Effects of different Temozolomide regimens on the efficacy and long-term survival of patients with glioma

Abstract

Objective To investigate the efficacy on the different Temozolomide regimens in the treatment of patients with glioma and the effect on long-term survival. Methods A retrospective study was performed on 86 cases of patients with glioma who were admitted from September 2014 to September 2015.There were 44 males and 42 females, aged(46.33±4.34) years old, ranging from 30 to 66 years old.Patients were randomly divided into the single drug treatment group and the combined treatment group, with 43 cases in each group.Patients of the single drug treatment group were given Temozolomide, the others in the combined treatment group were given Temozolomide combined with Bevacizumab.The short-term treatment effect, 3-year follow-up survival rate, recurrence rate, KPS score and adverse reactions were compared between the two groups. Results The total effective rate of short-term treatment in the combined treatment group was 93.0%(40/43) higher than that in the single drug treatment group 72.1%(31/43), with statistically significant difference(P 0.05). The 3-year follow-up survival rate of the combined treatment group was 60.5%(26/43), higher than that of the single drug treatment group 48.8%(21/43), and the recurrence rate was 11.6%(5/43), lower than that of the single drug treatment group 23.2%(10/43), and the difference was statistically significant(P 0.05). After intervention, the KPS scores[(76.53±11.90) and(88.91±10.58)]of the patients in the two groups were higher than those before intervention[(67.64±12.77) and(66.90±11.36)]. After intervention, the KPS scores[(88.91±10.58) of the patients in the combined treatment group were higher than those in the single drug treatment group(76.53±11.90), and the difference was statistically significant(P<0.05). The adverse reactions of the two groups were mainly nausea, vomiting, leucopenia, etc., the adverse reactions were mild, both of them were Grade Ⅰ or GradeⅡ, which could be relieved after symptomatic treatment, without Grade Ⅲ, Grade Ⅳ or Grade Ⅴ hematological adverse reactions. Conclusion Temozolomide combined with Bevacizumab in the treatment of glioma can achieve better therapeutic effect, the long-term survival rate of patients is higher, and the quality of life is better. Key words: Temozolamide; Bevacizumab; Glioma; Curative effect; Survival rates